Lowe, Alarice Cheng-Yi

TBCRC 022: Phase II trial of neratinib for patients (Pts) with human epidermal growth factor receptor 2 (HER2+) breast cancer and brain metastases (BCBM).

Gelman, Rebecca , Krop, Ian E. , Melisko, Michelle , Agar, Nathalie Y.R. , Blackwell, Kimberly , Connolly, Roisín M. , Poznak, Catherine Van , Puhalla, Shannon, Ryabin, Nicole, Lawler, Elizabeth S, Ibrahim, Nuhad K. , Liu, Minetta C. , Agar, Nathalie Y R , Freedman, Rachel A. , Wefel, Jeffrey S. , Lowe, Alarice Cheng-Yi , Niravath, Polly Ann , Wolff, Antonio C. , Winer, Eric P. , Lin, Nancy U.

Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: 528-528

10.1200/jco.2014.32.15_suppl.528